The Expected License Agreement Would Position Oragenics as the Only Company with Therapeutic Strategies Targeting TBI-Induced Inflammation on Both Sides of the Blood-Brain Barrier

Sarasota, FL and San Diego, CA, May 07, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a clinical-stage biopharmaceutical company pioneering neurological therapeutics, and Sigyn Therapeutics, Inc. (OTCQB:SIGY) ("Sigyn"), a developer of extracorporeal therapies, today announced the signing of a Letter of Intent ("LOI") under which Oragenics expects to license from Sigyn, certain disease indications of CardioDialysis™, a blood purification technology that enables the broad-spectrum clearance of inflammatory and pathogenic molecules from the bloodstream.

Under the terms of the proposed license agreement, Oragenics would receive an exclusive license from Sigyn to develop and commercialize CardioDialysis™ for the treatment of Traumatic Brain Injury (TBI) and other chronic neurodegenerative diseases.